Michael Barbella, Managing Editor10.26.23
Biomedical Bonding has been granted a patent from the United States Patent and Trademark Office for its primer composition.
The patent covers the company's primer composition that may be applied to tissue to increase bond strength between the tissue and a patch, filler, or a supporting material. The primer comprises a dithiol component and an allyl containing component together with a photo initiator. The primer is a key part of BMB’s Bonevolent technology that allows surgeons to do on-site customizable bone fracture fixations.
“Our IP protection is now broader and targets key geographical areas. We look forward to introducing our appreciated novel technology to the U.S. market,” Biomedical Bonding CEO Evelina Mikaelson said.
Bonevolent Adhfix can adapt to any bone shape and possesses high load-bearing properties. As an implant, AdhFix takes leverage of mechanical fixators and eliminate the use of metal plates, according to BIomedical Bonding. The product has excellent compatibility to soft tissue, thereof minimizing adverse effects associated to standard-of-care metal plates.
Biomedical Bonding AB is a platform-based medtech company developing medical adhesive fixators and surgical methodologies with focus on hard tissue restorations. Its technological platform, Bonevolent, stands for a paradigm shift in personalized surgical interventions. The privately held company is headquartered in Stockholm, Sweden.
The patent covers the company's primer composition that may be applied to tissue to increase bond strength between the tissue and a patch, filler, or a supporting material. The primer comprises a dithiol component and an allyl containing component together with a photo initiator. The primer is a key part of BMB’s Bonevolent technology that allows surgeons to do on-site customizable bone fracture fixations.
“Our IP protection is now broader and targets key geographical areas. We look forward to introducing our appreciated novel technology to the U.S. market,” Biomedical Bonding CEO Evelina Mikaelson said.
Bonevolent Adhfix can adapt to any bone shape and possesses high load-bearing properties. As an implant, AdhFix takes leverage of mechanical fixators and eliminate the use of metal plates, according to BIomedical Bonding. The product has excellent compatibility to soft tissue, thereof minimizing adverse effects associated to standard-of-care metal plates.
Biomedical Bonding AB is a platform-based medtech company developing medical adhesive fixators and surgical methodologies with focus on hard tissue restorations. Its technological platform, Bonevolent, stands for a paradigm shift in personalized surgical interventions. The privately held company is headquartered in Stockholm, Sweden.